Table 3.
Placental growth factor (PlGF).
| UNIT OF MEASUREMENT | STUDY ID | STUDY DESIGN | VALUE |
OR, PLR, NLR, PPV, NPV | SENSITIVITY, SPECIFICITY | TRIMESTER (GW) | NUMBER OF PARTICIPANTS |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| no condition | PE |
no PE | PE |
||||||||
| any GW | ⩽34 weeks (early onset PE) | any GW | ⩽34 weeks (early onset PE) | ||||||||
| pg/ml | Widmer et al. (2015) | Multicenter, prospective | 84.6 (35.4–167.8) | 55.9 (23.5–117.4) | 59.9 (24.8–122.2) | PLR, NLR, ORs, sensitivity and specificity provided by cut-off only | 1st–2nd (<20 GW) | 4929 | 198 | 47 | |
| 456.3 (280.5–696.0) | 253.7 (122.4–396.0) | 153.6 (81.7–356.0) | 2nd (23–27 GW) | ||||||||
| 513.8 (276.1–894.2) | 152.5 (79.0–249.7) | 3rd (32–35 GW) | |||||||||
| Honigberg et al. (2016) | Multicenter, prospective, | 14.6 | 11.8 | PPV = 10.2% NPV = 93.6% |
56.4%, 56.4% | 1st-2nd (10–18 GW) | 2153 | 184 | 18 | ||
| 37.3 | 26.8 | PPV = 11.9% NPV = 94.7% |
60.9%, 61.0% | 2nd (18–26 GW) | |||||||
| -6.3 | -15.8, p < 0.0001 | PPV = 10.4% NPV = 94.7% |
59.1%, 59.1% | 2nd-3rd (26–35 GW) | |||||||
| Coolman et al. (2012) | Monocenter, population-based prospective cohort | 43.5 (21.9–120) | 36.3 (17.4–111.6) | n/a | 1st-2nd (<18 GW) | 7327 | 167 | 23 | |||
| 203 (111–415) | 149 (64.8–341) | 2nd (18–25 GW) | |||||||||
| Herraiz et al. (2018) | Monocenter, prospective observational cohort | 378.1 (median IQR 264.5) | 96.2, median IQR 121.6 (intermediate), 262.5, median IQR 357.2 (late) | 38.9, median IQR 41.2 | n/a | 2nd-3rd (24–28 GW) | 5365 | 236 | 14 | ||
| Schneuer et al. (2013) | Monocenter, population-based prospective cohort | 24.1 (18.3, 31.7) | 20.7 (17.2, 32.6) | PPV = 3.7% (1.2, 8.4) NPV = 97.5% (96.8, 98.1) PLR = 1.47 |
7.4% (2.4, 17.3) | 1st-2nd (12–14 GW) | 2468 | 68 | |||
| Boutin et al., 2020 | Monocenter, prospective cohort | 35.5 (27.3–46.3) | 21.6 (15.0–31.0) | n/a | 1st (11–13 GW) | 3764 | 225 | 29 | |||
| Kusanovic et al. (2009) | Monocenter, prospective cohort | 33.8 (0.0–451.9) | 23.5 (0.0–77.1) | PPV = 5.9%, NPV = 97.6%, PLR = 1.6 (1.3–1.9%), NLR = 0.6 (0.4–0.8_ | 62.9% 60.4% |
1st-2nd (6–15 GW) | 1560 | 62 | |||
| 329.8 (22.3–2894.4) | 213.9 (0.0–969.6) | PPV = 8%, NPV = 97.5%, PLR = 2.2 (1.7–2.7%), NLR = 0.6 (0.5–0.8) | 51.6% 76.4% |
2nd (20–25 GW) | |||||||
| Ghosh et al. (2013) | Monocenter, prospective cohort | <144 in 176/426 underweight women, 394/976 normal women, 68/192 overweight, 28/84 obese | PlGF <144 and EOPE: OR in obese/overweight women = 7.64 (5.34–10.12) OR in normal/underweight women = 2.95 (1.74–4.26) |
n/a | 2nd (20–22 GW) | 1657 | 21 | ||||
| Kumar et al. (2017) | Monocenter, observational, prospective cohort | 37.31 ± 13.28, median = 34.2 | 30.42 ± 10.22, median = 34.2 | OR = 3.57 (1.36–6.84) | n/a | 1st (11–13 GW) | 1206 | 208 (HDP) | 74 (HDP) | ||
| Kenny et al. (2014) | Multicenter, prospective, non-interventional cohort | 977 (545–1649) | 642 (347–1252) | n/a | 2nd (14–16 GW) | 5317 | 306 | 28 | |||
| Chaiyasit et al., 2022 | Multicenter, prospective, non-interventional cohort | 37.32 (27.54–50.06) | 26.88 (18.89–237.61) | n/a | 1st (11–13 GW) | 7736 | 141 | ||||
| ng/ml | Vieira et al. (2017) | Multicenter, prospective, cohort | 1.01 (0.56–1.72) (normal BMI), 1.00 (0.55–1.70) (obese) | 0.71 (0.41–1.68) (normal BMI), 0.66 (0.31–1.31) (obese) | OR = 1.25 (1.00–1.56) in normal BMI OR = 1.82 (1.37–2.42) in obese women |
n/a | 1st-2nd (10–16 GW) | 3767 | 182 | ||
| MoM | Sonek et al. (2018) | Monocenter, prospective observational cohort | 1.01 (0.81–1.27) | Late onset: 1.07 (0.84–1.28) | 0.68 (0.38–1.17) | n/a | 1st (11–13 GW) | 1022 | Late onset:46 | 13 | |
| Hu et al. (2021) | Multicenter, prospective, population-based | 0.99 (0.73–1.32) | Late onset: 0.83 (0.53–1.09) term PE | 0.91 (0.63–1.18) | n/a | 1st (11–13 GW) | 8333 | Late onset: 195 | 117 | ||
| Hanchard et al. (2020) | Monocenter, prospective cohort | 1.09 (1.06–1.12) | 0.95 (0.84–1.06) | OR = 0.258 (0.093–0.711) | n/a | 1st-2nd (10–14 GW) | 1086 | 55 (HDP) | |||
| Panaitescu et al. (2018) | Multicenter, prospective, observational | 1.019 (0.559–1.832) | 0.334 (0.198–0.556) | n/a | 3rd (35–37 GW) | 13078 | 272 | ||||
| no value provided | O'Gorman et al. (2017) | Multicenter, prospective, non-interventional | n/a | 1st (11–13 GW) | 8297 | 239 | 76 | ||||
| Boutin et al. (2018) | Monocenter, prospective cohort | n/a | 1st (11–13 GW) | 4420 | 232 | 30 | |||||
| Chaemsaithong et al. (2019) | Monocenter, prospective, non-interventional cohort | n/a | 1st (11–13 GW) | 3982 | 41 | ||||||